Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 2,278 Shares of Stock

Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Curt A. Herberts III sold 2,278 shares of the business’s stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $18.30, for a total transaction of $41,687.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of NASDAQ:SGMO opened at $16.95 on Friday. The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 0.13. Sangamo Therapeutics Inc has a 1 year low of $4.05 and a 1 year high of $27.50.

How to Become a New Pot Stock Millionaire

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.03. The company had revenue of $13.08 million for the quarter, compared to analyst estimates of $11.10 million. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. The business’s revenue for the quarter was up 46.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.14) earnings per share. equities research analysts forecast that Sangamo Therapeutics Inc will post -0.15 earnings per share for the current year.

Several analysts recently issued reports on the stock. BidaskClub lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. ValuEngine upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Wedbush restated a “neutral” rating and issued a $6.00 price objective on shares of Sangamo Therapeutics in a report on Monday, February 12th. Zacks Investment Research lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Finally, Jefferies Group restated a “buy” rating on shares of Sangamo Therapeutics in a report on Friday, February 23rd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $20.83.

A number of large investors have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. increased its stake in Sangamo Therapeutics by 29.3% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 18,962 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 4,300 shares during the period. Nationwide Fund Advisors increased its stake in Sangamo Therapeutics by 13.5% during the third quarter. Nationwide Fund Advisors now owns 44,892 shares of the biopharmaceutical company’s stock worth $673,000 after purchasing an additional 5,337 shares during the period. Swiss National Bank increased its stake in Sangamo Therapeutics by 3.9% during the fourth quarter. Swiss National Bank now owns 142,460 shares of the biopharmaceutical company’s stock worth $2,336,000 after purchasing an additional 5,400 shares during the period. Rhumbline Advisers increased its stake in Sangamo Therapeutics by 7.4% during the third quarter. Rhumbline Advisers now owns 88,816 shares of the biopharmaceutical company’s stock worth $1,332,000 after purchasing an additional 6,125 shares during the period. Finally, California State Teachers Retirement System increased its stake in Sangamo Therapeutics by 5.0% during the third quarter. California State Teachers Retirement System now owns 132,741 shares of the biopharmaceutical company’s stock worth $1,991,000 after purchasing an additional 6,360 shares during the period. Institutional investors own 64.68% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 2,278 Shares of Stock” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3337686/insider-selling-sangamo-therapeutics-inc-sgmo-vp-sells-2278-shares-of-stock.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Insider Selling: GoDaddy  Insider Sells 10,000 Shares of Stock
Insider Selling: GoDaddy Insider Sells 10,000 Shares of Stock
Boingo Wireless  CEO David Hagan Sells 19,833 Shares
Boingo Wireless CEO David Hagan Sells 19,833 Shares
Theravance Biopharma  Reaches New 52-Week High and Low at $21.27
Theravance Biopharma Reaches New 52-Week High and Low at $21.27
Heinz  Sets New 1-Year High and Low at $57.55
Heinz Sets New 1-Year High and Low at $57.55
Building Materials  Reaches New 1-Year High and Low at $17.90
Building Materials Reaches New 1-Year High and Low at $17.90
Compass Diversified Holdings  Expected to Post Quarterly Sales of $353.71 Million
Compass Diversified Holdings Expected to Post Quarterly Sales of $353.71 Million


© 2006-2018 Ticker Report. Google+.